George Golumbeski

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ.

Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA.

Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA.

National Audubon Society, Inc. conserves and restores natural ecosystems. The firm preserves species of birds, other animals, and their natural habitats. Its projects include saving habitat in the everglades, arctic wildlife refuge, long island sound, and mississippi river basin. The company was founded in 1905 by George Bird Grinnell and is headquartered in New York City, NY.

Promega Corp. manufactures enzyme systems. Its products include cell biology, nucleic acid analysis, drug development, molecular diagnostics, and lab equipment and supplies. The company was founded by William Alderman Linton in 1978 and is headquartered in Madison, WI.

SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI.

Nabriva Therapeutics GmbH is a clinical-stage biopharmaceutical company, which engages in the research and development of novel anti-infective agents to treat serious infections. It focuses on the pleuromutilin class of antibiotics. The company was founded by Rodger Novak in October 2005 and is headquartered in Vienna, Austria.

Part of Merck KGaA, EMD Pharmaceuticals, Inc. is a company that manufactures pharmaceutical preparations. The company is based in Durham, NC. The company was founded by Nancy J. Wysenski.

BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart.

BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal.

Part of Thermo Fisher Scientific, Inc., Pierce Biotechnology, Inc. is a company that offers a range of innovative, high-quality products for protein biology research. The company is based in Rockford, IL. The company's products include Pierce antibodies, SuperSignal chemiluminescent substrates, Pierce BCA protein assays, and other research tools and reagents.

Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA.

Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland.

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA.

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

Tusk Therapeutics Ltd. operates as a immuno-oncology company, focused on discovering and developing therapeutic antibodies. It provides immune modulating cancer therapeutics. The company is headquartered in Stevenage, the United kingdom.

KSQ Therapeutics, Inc. develops and deploys precision functional genomics to discover therapies that transform patient lives. The company was founded by Tim Wang and is headquartered in Cambridge, MA.

Verseau Therapeutics, Inc. provides immuno-therapy services. The company was founded by Daniel Anderson, Robert Langer, Igor Feldman, and Tatiana Novobrantseva in 2017 and is headquartered in Bedford, MA.

Vertex Ventures HC (Vertex Ventures) is a venture capital subsidiary of Vertex Venture Holdings Ltd founded in 2014. The firm is headquartered in San Francisco, California.

Chroma Medicine, Inc. is a biotechnology company that pioneers a new class of genomic medicines using epigenetics to deliver precise, programmable single-dose therapeutics while preserving genomic integrity. The company is based in Cambridge, MA and has subsidiaries in Italy. The company's modular platform enables the development of medicines that can address a wide range of complex diseases, whether they require silencing, activation, or targeting multiple genes at once. Chroma Medicine was founded by the world's foremost experts in genomic research and is led by a veteran team of industry leaders and scientists with deep experience in genomic medicine, drug discovery, and development. Catherine Stehman-Breen has been the CEO of the company since 2020.

Part of Carrick Therapeutics Ltd., Carrick Therapeutics UK Ltd. is a clinical-stage biopharmaceutical company based in Oxford, UK. Carrick Therapeutics translates in-house and in-licensed assets to target the most aggressive and resistant forms of cancer, working in combination with existing oncology drugs to address unmet patient needs. The British company focuses on developing innovative therapies to improve patient outcomes in oncological therapy. The company's therapies have potential in advanced breast, prostate, and ovarian cancers, with further potential in pancreatic and Ewing's sarcoma. Timothy R. Pearson has been the CEO of the company since 2019.

Actio Biosciences, Inc. is an American precision medicine company that focuses on developing new therapeutics for rare and common diseases by targeting shared genetics. Actio Biosciences was founded in October 2021 and is based in an undisclosed location. The company applies its expertise in genetics, drug discovery, and data sciences to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward potent and precisely targeted therapeutics. The company is led by leaders in genetics and drug development and backed by top healthcare investors.

Ananke Therapeutics, Inc. develops therapeutic medicines for patients.